Gain Therapeutics Announces Additional Preclinical Data and Phase 1b Study Design for GT-02287 in Parkinson's Disease

Gain Therapeutics, Inc.

GT-02287 showed disease-modifying potential in GBA1 and idiopathic Parkinson's disease models, with biomarkers statistically reduced and lasting after drug washout.
Phase 1b study ongoing; early biomarker analysis of enrolled participants expected mid-2025, including GBA1 mutation carriers and non-carriers.
Complete Phase 1b endpoint analysis after 90 days of treatment anticipated in Q4 2025, guiding Phase 2 design in H2 2025.
Oral presentation at AD/PD 2025 highlighted behavioral and biomarker data supporting GT-02287's disease-modifying capacity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.